In a new disclosure filed today, U.S. Senator Tommy Tuberville reported the purchase of $1,001 - $15,000 of Humacyte Inc, in a trade that took place on March 21. Since that trade was made, the stock has...
Monday U.S. Economic Lookahead Home builder confidence index (Feb.) Featured Earnings ...
Aeglea (AGLE) delivered earnings and revenue surprises of -5.26% and 16.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 1,860% and 51.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...
Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 12.50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 0.65% and 8.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?